Natasha N. Pettit

Natasha N. Pettit

Auto-generated profile, based on publicly available information

Natasha N. Pettit

Department of Pharmacy, University of Chicago Medicine, Chicago, IL, USA

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2017 in American Journal of Respiratory and Critical Care Medicine
Verified
Journal Article
Closed access
MCMatthew M. Churpek
Matthew M. Churpek
ASAshley Snyder
Ashley Snyder
XHXuan Han
Xuan Han
SSSarah Sokol
Sarah Sokol
NPNatasha Pettit
Natasha Pettit
DEDana P. Edelson
Dana P. Edelson
Rationale: The 2016 definitions of sepsis included the quick Sepsis-related Organ Failure Assessment (qSOFA) score to identify high-risk patients outside the intensive care unit (ICU). Objectives: We sought to compare qSOFA with other commonly used early warning scores. Methods: All admitted patients who first met the criteria for suspicion of infection in the emergency department (ED) or hospital wards from November 2008 until January 2016 were included. The qSOFA, Systemic Inflammatory Response Syndrome (SIRS), Modified Early Warning Score (MEWS), and the National Early Warning Score (NEWS) were compared for predicting death and ICU transfer. Measurements and Main Results: Of the 30,677 included patients, 1,649 (5.4%) died and 7,385 (24%) experienced the composite outcome (death or ICU transfer). Sixty percent (n = 18,523) first met the suspicion criteria in the ED. Discrimination for in-hospital mortality was highest for NEWS (area under the curve [AUC], 0.77; 95% confidence interval [CI], 0.76–0.79), followed by MEWS (AUC, 0.73; 95% CI, 0.71–0.74), qSOFA (AUC, 0.69; 95% CI, 0.67–0.70), and SIRS (AUC, 0.65; 95% CI, 0.63–0.66) (P < 0.01 for all pairwise comparisons). Using the highest non-ICU score of patients, ≥2 SIRS had a sensitivity of 91% and specificity of 13% for the composite outcome compared with 54% and 67% for qSOFA ≥2, 59% and 70% for MEWS ≥5, and 67% and 66% for NEWS ≥8, respectively. Most patients met ≥2 SIRS criteria 17 hours before the combined outcome compared with 5 hours for ≥2 and 17 hours for ≥1 qSOFA criteria. Conclusions: Commonly used early warning scores are more accurate than the qSOFA score for predicting death and ICU transfer in non-ICU patients. These results suggest that the qSOFA score should not replace general early warning scores when risk-stratifying patients with suspected infection.

26 June 2020 in Obesity
Verified
Journal Article
Closed access
PDF file
NPNatasha N. Pettit
Natasha N. Pettit
EMErica L. MacKenzie
Erica L. MacKenzie
JRJessica P. Ridgway
Jessica P. Ridgway
KPKenneth Pursell
Kenneth Pursell
DADaniel Ash
Daniel Ash
MPMai Tuyet Pho
Mai Tuyet Pho

1 July 2020 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
CLChristopher J Lehmann
Christopher J Lehmann
MPMai T Pho
Mai T Pho
DPDavid Pitrak
David Pitrak
JRJessica P Ridgway
Jessica P Ridgway
NPNatasha N Pettit
Natasha N Pettit
Community-acquired coinfection in coronavirus disease 2019 (COVID-19) is not well defined. Current literature describes coinfection in 0–40% of COVID-19 patients. In this retrospective report, coinfection was identified in 3.7% of patients and 41% of patients admitted to intensive care (P < .005). Despite infrequent coinfection, antibiotics were used in 69% of patients.

13 August 2020 in Journal of Medical Virology
Verified
Journal Article
Closed access
PDF file
NPNatasha N. Pettit
Natasha N. Pettit
CNCynthia T. Nguyen
Cynthia T. Nguyen
GMGökhan M. Mutlu
Gökhan M. Mutlu
DWDavid Wu
David Wu
LKLucas Kimmig
Lucas Kimmig
KPKenneth Pursell
Kenneth Pursell

6 December 2020 in Clinical Infectious Diseases
Verified
Journal Article
Closed access
NPNatasha N Pettit
Natasha N Pettit
JPJennifer Pisano
Jennifer Pisano
CNCynthia T Nguyen
Cynthia T Nguyen
ALAlison K Lew
Alison K Lew
AHAniruddha Hazra
Aniruddha Hazra
KMKathleen M Mullane
Kathleen M Mullane
Background: Remdesivir (RDV) is US FDA approved for coronavirus disease 2019 (COVID-19) but not recommended in severe renal impairment (SRI, Creatinine clearance <30mL/min or requiring renal replacement therapy). Few studies have evaluated RDV in patients with SRI.Methods: Hospitalized patients who received RDV between 1 May 2020 and 31 October 2020 were analyzed in a retrospective chart review. We compared incident adverse events (AEs) in patients with and without SRI, including hepatotoxicity, nephrotoxicity, any reported AE, mortality, and length of stay.Results: Of a total of 135 patients, 20 had SRI. Patients with SRI were significantly older (70 vs 54 years, P = .0001). The incidence of possible AEs was 30% among those with SRI vs 11% without (P = .06). Liver function test (LFT) elevations occurred in 10% vs 4% (P = .28), and serum creatinine (SCr) elevations in 27% vs 6% (P = .02) of patients with SRI vs without, respectively. LFT and SCr elevations were not attributed to RDV in either group.Mortality and length of stay were consistent with historical controls.Conclusions: RDV AEs occurred infrequently and overall were not significantly different between those with and without SRI. While more of patients with SRI experienced SCr elevations, 3 (75%) patients had acute kidney injury prior to RDV. The use of RDV in this small series of patients with SRI appeared to be relatively safe, and the potential benefit outweighed the theoretical risk of liver or renal toxicity. Additional studies are needed to confirm this finding.

2 June 2021 in BMC Infectious Diseases
Verified
Journal Article
Open access
PDF file
NPNatasha N. Pettit
Natasha N. Pettit
CNCynthia T. Nguyen
Cynthia T. Nguyen
ALAlison K. Lew
Alison K. Lew
PBPalak H. Bhagat
Palak H. Bhagat
ANAllison Nelson
Allison Nelson
JPJade Pagkas-Bather
Jade Pagkas-Bather
Background: Empiric antibiotics for community acquired bacterial pneumonia (CABP) are often prescribed to patients with COVID-19, despite a low reported incidence of co-infections. Stewardship interventions targeted at facilitating appropriate antibiotic prescribing for CABP among COVID-19 patients are needed. We developed a guideline for antibiotic initiation and discontinuation for CABP in COVID-19 patients. The purpose of this study was to assess the impact of this intervention on the duration of empiric CABP antibiotic therapy among patients with COVID-19. Methods: This was a single-center, retrospective, quasi-experimental study of adult patients admitted between 3/1/2020 to 4/25/2020 with COVID-19 pneumonia, who were initiated on empiric CABP antibiotics. Patients were excluded if they were initiated on antibiotics > 48 h following admission or if another source of infection was identified. The primary outcome was the duration of antibiotic therapy (DOT) prior to the guideline (March 1 to March27, 2020) and after guideline implementation (March 28 to April 25, 2020). We also evaluated the clinical outcomes (mortality, readmissions, length of stay) among those initiated on empiric CABP antibiotics. Results: A total of 506 patients with COVID-19 were evaluated, 102 pre-intervention and 404 post-intervention. Prior to the intervention, 74.5% (n = 76) of patients with COVID-19 received empiric antibiotics compared to only 42% of patients post-intervention (n = 170), p < 0.001. The median DOT in the post-intervention group was 1.3 days shorter (p < 0.001) than the pre-intervention group, and antibiotics directed at atypical bacteria DOT was reduced by 2.8 days (p < 0.001). More patients in the post-intervention group were initiated on antibiotics based on criteria consistent with our guideline (68% versus 87%, p = 0.001). There were no differences between groups in terms of clinical outcomes. Conclusion: Following the implementation of a guideline outlining recommendations for initiating and discontinuing antibiotics for CABP among COVID-19 inpatients, we observed a reduction in antibiotic prescribing and DOT. The guideline also resulted in a significant increase in the rate of guideline-congruent empiric antibiotic initiation.